AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29758039 — intervention group
Group type: COMPARATOR
Intervention: Control (0.9% saline)
Number of subjects: 120
Study 27159993 — intervention group
Group type: EXPERIMENTAL
Intervention: Sativex(®) oral spray, up to 12 sprays/day for 12 weeks
Number of subjects: 26
Study 27159993 — intervention group
Group type: COMPARATOR
Intervention: Placebo oral spray, up to 12 sprays/day for 12 weeks
Number of subjects: 26
Study 27159993 — intervention group
Group type: EXPERIMENTAL
Intervention: Sativex(®)
Number of subjects: 26
Study 27159993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 25874878 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week cognitive-behavioral lifestyle intervention
Number of subjects: 135
Study 25874878 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 135
Study 23579427 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose alcohol (0.8 g/kg)
Number of subjects: 48
Study 23579427 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose alcohol (0.4 g/kg)
Number of subjects: 48
Study 23579427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 23579427 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive alcohol expectancies
Number of subjects: 48
Study 23579427 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol dose and outcome expectancies
Number of subjects: 48
Study 21397257 — intervention group
Group type: EXPERIMENTAL
Intervention: χ‐configuration (group NS)
Number of subjects: 30
Study 21397257 — intervention group
Group type: COMPARATOR
Intervention: Standard femoro‐jugular VV‐ECMO (group C)
Number of subjects: 30
Study 20005375 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN with alanyl‐glutamine (Gln) dipeptide
Number of subjects: 65
Study 20005375 — intervention group
Group type: COMPARATOR
Intervention: Traditional TPN support
Number of subjects: 65
Study 17476012 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation and management of superior vena cava syndrome
Number of subjects: 1
Study 15126724 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (not specified in detail)
Number of subjects: 540
Study 11202126 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping skills training
Number of subjects: 120
Study 11202126 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy
Number of subjects: 120
Study 11202126 — intervention group
Group type: COMPARATOR
Intervention: Unspecific supportive control therapy
Number of subjects: 120
Study 9506598 — intervention group
Group type: EXPERIMENTAL
Intervention: Home rehabilitation (early supported discharge with continuity of rehabilitation at home for 3 to 4 months)
Number of subjects: 81
Study 9506598 — intervention group
Group type: COMPARATOR
Intervention: Routine rehabilitation service (hospital, day care, and/or outpatient care)
Number of subjects: 81
Study 7492128 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine, 0.5 mg twice daily
Number of subjects: 41
Study 7492128 — intervention group
Group type: COMPARATOR
Intervention: Topical emollients (Control)
Number of subjects: 41
Study 7492128 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 41
Study 2353183 — intervention group
Group type: EXPERIMENTAL
Intervention: Bubble oxygenator
Number of subjects: 96
Study 2353183 — intervention group
Group type: EXPERIMENTAL
Intervention: Membrane oxygenator
Number of subjects: 96
Study 2353183 — intervention group
Group type: COMPARATOR
Intervention: Control (thoracotomy without CPB)
Number of subjects: 96
Study 232697 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg pivmecillinam four times daily for seven days
Number of subjects: 100
Study 232697 — intervention group
Group type: COMPARATOR
Intervention: 500 mg ampicillin four times daily for seven days
Number of subjects: 100
Study 31727676 — intervention group
Group type: EXPERIMENTAL
Intervention: GX-188E injection
Number of subjects: 72
Study 30632971 — intervention group
Group type: EXPERIMENTAL
Intervention: QuitIT game (along with Standard Care: telecounseling and cessation pharmacotherapies)
Number of subjects: 42
Study 30632971 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (telecounseling and cessation pharmacotherapies)
Number of subjects: 42
Study 30632971 — intervention group
Group type: EXPERIMENTAL
Intervention: QuitIT game
Number of subjects: 42
Study 28283606 — intervention group
Group type: EXPERIMENTAL
Intervention: rCBV=0.32
Number of subjects: 47
Study 28283606 — intervention group
Group type: EXPERIMENTAL
Intervention: rCBV=0.34
Number of subjects: 47
Study 28283606 — intervention group
Group type: EXPERIMENTAL
Intervention: rCBF=0.30
Number of subjects: 47
Study 28283606 — intervention group
Group type: EXPERIMENTAL
Intervention: rCBF=0.32
Number of subjects: 47
Study 28283606 — intervention group
Group type: EXPERIMENTAL
Intervention: rCBF=0.34
Number of subjects: 47
Study 26345179 — intervention group
Group type: EXPERIMENTAL
Intervention: MOMCare (n = 83)
Number of subjects: 168
Study 26345179 — intervention group
Group type: COMPARATOR
Intervention: MSS-Plus (n = 85)
Number of subjects: 168
Study 25927321 — intervention group
Group type: EXPERIMENTAL
Intervention: Genuair (multidose inhaler)
Number of subjects: 128
Study 25927321 — intervention group
Group type: COMPARATOR
Intervention: Breezhaler (single-dose inhaler)
Number of subjects: 128
Study 25927321 — intervention group
Group type: EXPERIMENTAL
Intervention: Genuair
Number of subjects: 128
Study 25927321 — intervention group
Group type: COMPARATOR
Intervention: Breezhaler
Number of subjects: 128
Study 24252663 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconference-based CBT
Number of subjects: 26
Study 24252663 — intervention group
Group type: COMPARATOR
Intervention: In-person CBT
Number of subjects: 26
Study 21262317 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg caffeine
Number of subjects: 20
Study 21262317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 17693459 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis (TL)
Number of subjects: 1050
Study 17693459 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (pPCI)
Number of subjects: 1050
Study 17693459 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis (TL) on-site
Number of subjects: 1050
Study 17693459 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted odds ratio for mortality in women
Number of subjects: 1050
Study 17139118 — intervention group
Group type: EXPERIMENTAL
Intervention: 11-item pre-interview questionnaire (11-Q)
Number of subjects: 245
Study 14644398 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol (500 mg per day)
Number of subjects: 165
Study 14644398 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (10 mg per day)
Number of subjects: 165
Study 14644398 — intervention group
Group type: COMPARATOR
Intervention: C. pneumoniae antibody positive patients
Number of subjects: 165
Study 14644398 — intervention group
Group type: COMPARATOR
Intervention: Probucol and Pravastatin
Number of subjects: 165
Study 10723666 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 200 mg dose of levofloxacin (LVFX)
Number of subjects: 56
Study 10723666 — intervention group
Group type: COMPARATOR
Intervention: 100 mg of levofloxacin (LVFX) administered twice a day for three days
Number of subjects: 56
Study 9780939 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral sagittal split osteotomy (BSSO)
Number of subjects: 124
Study 8160955 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl 10 micrograms/ml with 0.1% bupivacaine (group FB)
Number of subjects: 90
Study 8160955 — intervention group
Group type: COMPARATOR
Intervention: Epidural fentanyl 10 micrograms/ml without bupivacaine (group F)
Number of subjects: 90
Study 3046646 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoprostenol (prostacyclin)
Number of subjects: 11
Study 3046646 — intervention group
Group type: COMPARATOR
Intervention: Tolazoline
Number of subjects: 11
Study 30075133 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid arch bars
Number of subjects: 50
Study 30075133 — intervention group
Group type: COMPARATOR
Intervention: Erich arch bars
Number of subjects: 50
Study 28393428 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthesia-Web
Number of subjects: 125
Study 28393428 — intervention group
Group type: COMPARATOR
Intervention: Brochure material
Number of subjects: 125
Study 26140524 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel 8 mg
Number of subjects: 0
Study 26140524 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel 12 mg
Number of subjects: 0
Study 26140524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26140524 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel
Number of subjects: 0
Study 24172555 — intervention group
Group type: EXPERIMENTAL
Intervention: iCare tonometer
Number of subjects: 83
Study 24172555 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsair tonometer
Number of subjects: 83
Study 24172555 — intervention group
Group type: COMPARATOR
Intervention: Perkins tonometer
Number of subjects: 83
Study 21177297 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg daily
Number of subjects: 200
Study 21177297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 18329627 — intervention group
Group type: EXPERIMENTAL
Intervention: Goldmann tonometry (GAT)
Number of subjects: 38
Study 18329627 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatonometry
Number of subjects: 38
Study 18329627 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic contour tonometry (DCT)
Number of subjects: 38
Study 18329627 — intervention group
Group type: COMPARATOR
Intervention: Pneumatonometry vs DCT
Number of subjects: 38
Study 18329627 — intervention group
Group type: COMPARATOR
Intervention: Correlation between IOP and corneal thickness
Number of subjects: 38
Study 16595614 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1,600 mg
Number of subjects: 46
Study 16595614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 14609606 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL cholesterol <70 mg/dl
Number of subjects: 0
Study 14609606 — intervention group
Group type: COMPARATOR
Intervention: Statin therapy with LDL cholesterol <100 mg/dl
Number of subjects: 0
Study 10898416 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 0
Study 10898416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10898416 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombocytopenia
Number of subjects: 0
Study 10898416 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudothrombocytopenia
Number of subjects: 0
Study 8769601 — intervention group
Group type: EXPERIMENTAL
Intervention: RSHZ19 (0.025‐10.0 mg/kg)
Number of subjects: 26
Study 8769601 — intervention group
Group type: EXPERIMENTAL
Intervention: RSHZ19 (10 mg/kg)
Number of subjects: 26
Study 8769601 — intervention group
Group type: EXPERIMENTAL
Intervention: RSHZ19 (5 mg/kg)
Number of subjects: 26
Study 8769601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 8311368 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking (20 or more cigarettes daily)
Number of subjects: 22071
Study 8311368 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking (fewer than 20 cigarettes daily)
Number of subjects: 22071
Study 8311368 — intervention group
Group type: EXPERIMENTAL
Intervention: Former smoking
Number of subjects: 22071
Study 8311368 — intervention group
Group type: COMPARATOR
Intervention: Never-smokers (reference group)
Number of subjects: 22071
Study 8311368 — intervention group
Group type: EXPERIMENTAL
Intervention: Total fatal stroke
Number of subjects: 22071
Study 2905133 — intervention group
Group type: COMPARATOR
Intervention: 20 mg temazepam (Planum)
Number of subjects: 14
Study 2905133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 29697011 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibralung (PEP and sound)
Number of subjects: 21
Study 29697011 — intervention group
Group type: COMPARATOR
Intervention: Vibralung (PEP only)
Number of subjects: 21
Study 29697011 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibralung
Number of subjects: 21
Study 29697011 — intervention group
Group type: COMPARATOR
Intervention: Vibratory vest therapy (Vest)
Number of subjects: 21
Study 27739142 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% lidocaine
Number of subjects: 77
Study 27739142 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (placebo)
Number of subjects: 77
Study 26284918 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 31
Study 26284918 — intervention group
Group type: COMPARATOR
Intervention: Insulin Glargine
Number of subjects: 31
Study 23471469 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 850
Study 20964769 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen alone (40 mg·kg(‐1) rectal)
Number of subjects: 0
Study 20964769 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen and intranasal fentanyl (1 mcg·kg(‐1))
Number of subjects: 0
Study 20964769 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen and intramuscular ketorolac (1 mg·kg(‐1))
Number of subjects: 0
Study 18211600 — intervention group
Group type: EXPERIMENTAL
Intervention: Feminine pads with absorbent gelling material
Number of subjects: 0
Study 18211600 — intervention group
Group type: COMPARATOR
Intervention: Feminine pads with cellulose absorbent cores
Number of subjects: 0
Study 18211600 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical in-use study with feminine pads
Number of subjects: 0
Study 17012138 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 43
Study 17012138 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 43
Study 17012138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 14524005 — intervention group
Group type: EXPERIMENTAL
Intervention: Gm allotypes
Number of subjects: 133
Study 14524005 — intervention group
Group type: EXPERIMENTAL
Intervention: Km allotypes
Number of subjects: 133
Study 10740141 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (initial dosage 4 mg/d, increased to 16 mg/d if tolerated)
Number of subjects: 270
Study 10740141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study 10740141 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 270
Study 8715233 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal group educational sessions emphasizing skills necessary to initiate and maintain breastfeeding
Number of subjects: 59
Study 8715233 — intervention group
Group type: COMPARATOR
Intervention: Five basic interventions (control group)
Number of subjects: 59
Study 1376362 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.5-8.0 mg)
Number of subjects: 6
Study 1376362 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone (5 and 10 mg)
Number of subjects: 6
Study 1376362 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.1 and 0.2 mg)
Number of subjects: 6
Study 1376362 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 6
Study 6722464 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous sphincterotomy
Number of subjects: 28
Study 6722464 — intervention group
Group type: EXPERIMENTAL
Intervention: Open sphincterotomy
Number of subjects: 28
Study 29850956 — intervention group
Group type: EXPERIMENTAL
Intervention: PEKK-made crowns and bridges (Pekkton ivory)
Number of subjects: 22
Study 29850956 — intervention group
Group type: COMPARATOR
Intervention: CoCr-made crowns
Number of subjects: 22
Study 30043449 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ house dust mite sublingual immunotherapy-tablet (10,000 JAU)
Number of subjects: 458
Study 30043449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 458
Study 26897452 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaw closure using an air-inflatable pneumatic actuator at 6-cm head elevation
Number of subjects: 6
Study 26897452 — intervention group
Group type: COMPARATOR
Intervention: Neutral occlusion at 6-cm head elevation
Number of subjects: 6
Study 26897452 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaw closure at 0-cm head elevation
Number of subjects: 6
Study 26897452 — intervention group
Group type: COMPARATOR
Intervention: Neutral occlusion at 0-cm head elevation
Number of subjects: 6
Study 26897452 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaw closure at 6-cm head elevation
Number of subjects: 6
Study 25280421 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc acetate preparation at a dose of 3 capsules/d for a total zinc content of 150 mg/d (Z group)
Number of subjects: 12
Study 25280421 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P group)
Number of subjects: 12
Study 22850072 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard 4-drug therapy (Metronidazole 500 mg/BD, Amoxicillin 1g/BD, Omeprazole 20mg/BD, Bismuth 240 mg/BD) + Lycopene (30 mg/daily)
Number of subjects: 54
Study 22850072 — intervention group
Group type: COMPARATOR
Intervention: Standard 4-drug therapy (Metronidazole 500 mg/BD, Amoxicillin 1g/BD, Omeprazole 20mg/BD, Bismuth 240 mg/BD)
Number of subjects: 54
Study 19549250 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-glucose infusion therapy
Number of subjects: 55
Study 19549250 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 55
Study 17906340 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting Cypher stents
Number of subjects: 350
Study 17906340 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 350
Study 15588161 — intervention group
Group type: EXPERIMENTAL
Intervention: Resection of colorectal cancer
Number of subjects: 20
Study 15588161 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric banding
Number of subjects: 20
Study 12046701 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlinear Wiener model of pure seizure activity
Number of subjects: 64
Study 12046701 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlinear Wiener model of pure background activity
Number of subjects: 64
Study 12046701 — intervention group
Group type: COMPARATOR
Intervention: Roessgen model
Number of subjects: 64
Study 10442414 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-saccade (0 degrees)
Number of subjects: 0
Study 10442414 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-saccade (30, 60, 90, 120, 150, 180 degrees)
Number of subjects: 0
Study 10442414 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral cues
Number of subjects: 0
Study 10442414 — intervention group
Group type: EXPERIMENTAL
Intervention: Central cues
Number of subjects: 0
Study 7842769 — intervention group
Group type: EXPERIMENTAL
Intervention: Bambuterol (20 mg tablet) - morning administration
Number of subjects: 29
Study 7842769 — intervention group
Group type: EXPERIMENTAL
Intervention: Bambuterol (20 mg tablet) - evening administration
Number of subjects: 29
Study 7842769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 2297349 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (3.8 g of n-3 fatty acids)
Number of subjects: 33
Study 7002197 — intervention group
Group type: EXPERIMENTAL
Intervention: peroral zinc sulphate
Number of subjects: 24
Study 7002197 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 31815641 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia (32 °C)
Number of subjects: 282
Study 31815641 — intervention group
Group type: COMPARATOR
Intervention: Moderate hypothermia (26 °C)
Number of subjects: 282
Study 27854382 — intervention group
Group type: EXPERIMENTAL
Intervention: CTG-STV (reduced fetal heart rate short-term variation)
Number of subjects: 310
Study 27854382 — intervention group
Group type: EXPERIMENTAL
Intervention: DV-p95 (early changes in fetal ductus venosus waveform)
Number of subjects: 310
Study 27854382 — intervention group
Group type: EXPERIMENTAL
Intervention: DV-no-A (late changes in fetal ductus venosus waveform)
Number of subjects: 310
Study 27854382 — intervention group
Group type: COMPARATOR
Intervention: Safety-net criteria (spontaneous decelerations in FHR)
Number of subjects: 310
Study 27854382 — intervention group
Group type: COMPARATOR
Intervention: Maternal reasons for delivery
Number of subjects: 310
Study 25840512 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction internal fixation
Number of subjects: 50
Study 25840512 — intervention group
Group type: COMPARATOR
Intervention: Closed reduction
Number of subjects: 50
Study 24007456 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg once daily (qd)
Number of subjects: 1549
Study 24007456 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride 1-4 mg qd
Number of subjects: 1549
Study 21309914 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow Band Imaging (NBI)
Number of subjects: 30
Study 21309914 — intervention group
Group type: EXPERIMENTAL
Intervention: Lugol chromo-endoscopy
Number of subjects: 30
Study 21309914 — intervention group
Group type: COMPARATOR
Intervention: White light
Number of subjects: 30
Study 19389416 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction pulse with increased contrast or dot density
Number of subjects: 0
Study 19389416 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction pulse with varying strength
Number of subjects: 0
Study 16677064 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support intervention (legal/financial training session followed by five small-group workshops)
Number of subjects: 48
Study 16677064 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support intervention
Number of subjects: 48
Study 16677064 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study 15841998 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal endoscopic sphenopalatine artery ligation (ESAL)
Number of subjects: 19
Study 15841998 — intervention group
Group type: COMPARATOR
Intervention: Conventional nasal packing (Merocel)
Number of subjects: 19
Study 11368130 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 320
Study 11368130 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg/day
Number of subjects: 320
Study 11368130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320